Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: J Steroid Biochem Mol Biol. 2013 Oct 29;142:155–170. doi: 10.1016/j.jsbmb.2013.09.008

Figure 10.

Figure 10

The relative risk (95% CIs) for nonvertebral fractures with each therapy is shown in this slide. Significant treatment effects were seen only with HT (including the WHI trial), alendronate (10–40 mg), risedronate and Tereperatide. *Denosumab: * Cummings et al N Engl J Med. 2009